EMMAC Presents to Scientific Committee (CSST) in Paris on Company’s Advancement of Scientific Research into the Therapeutic Benefits of Medical Cannabis

LONDON–(BUSINESS WIRE)–EMMAC Life Sciences Ltd (“EMMAC” or the “Company”), the European
independent medical cannabis company, announces that on Wednesday 15th
May, the Company presented to the French Scientific Committee (CSST),
regarding EMMAC’s role in advancing scientific research into the medical
usage of cannabis for the welfare of patients. The CSST, appointed by
the Drug and Safety Agency (ANSM) is working to provide French
authorities with recommendations concerning the opening of the French
medical cannabis market. Dr Barbara Pacchetti, Chief Scientific Officer
at EMMAC, outlined the Company’s vision to bring together cutting-edge
scientific research with the latest innovations in cannabis cultivation,
extraction and production. EMMAC joined six other companies invited to
present to the CSST, including Tilray, Canopy Growth, Aurora Cannabis
Inc., and Bedrocan. The full presentation to the CSST can be found here.

Antonio Costanzo, CEO of EMMAC, commented: “We are grateful for
the opportunity to demonstrate to the CSST how EMMAC is focussed on
advancing research and development to improve the industry’s
understanding of the medical benefits of cannabis. EMMAC believes that
the growth of the medical cannabis sector has to be underpinned by the
most robust science and is working with leading academic institutions
across Europe to advance what we consider to be a huge potential market
with significant public health benefits for patients and clinicians.”


EMMAC is the European independent medical cannabis company, working to
join together the latest science and research with cutting-edge
cultivation, extraction and production. With supply and distribution
partnerships throughout Europe, EMMAC is working to establish itself as
both a thought leader in the industry, as well as the European leader in
the production and supply of medical cannabis, hemp and other derivative


All statements, other than statements of historical fact, in this
news release are forward-looking statements that involve various risks
and uncertainties, including, without limitation, statements regarding
potential values, the future plans and objectives of EMMAC Life Sciences
Ltd. There can be no assurance that such statements will prove to be
accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those
anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions
of management on the dates they are made and are expressly qualified in
their entirety by this notice. EMMAC Life Sciences Ltd assumes no
obligation to update forward-looking statements should circumstances or
management’s estimates or opinions change.


Scientific enquiries


Henry Harrison-Topham / Jamie Hooper
/ Catriona Flint
Tel: +44 (0) 20 7466 5000